Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors

NCT06398418 is registered in ClinicalTrials.gov with Rise Therapeutics LLC as lead sponsor.

NCT NCT06398418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06398418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors
Lead sponsor
Rise Therapeutics LLC
Phase
Phase 1
Overall status
Recruiting
Start date
August 1, 2025
Completion date
September 15, 2029
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoma, basal cell cancer, melanoma, solid tumor, solid tumor, adult, squamous cell cancer